AUM Pharmacy
Health Hub
Search Icon

AUM Pharmacy

Hi there!

Hello, Login
All Categories
VisaVisaVisa
fallback

Ignalis-M 50mg/500mg Tablet ER

Prescription Icon
Prescription Required

Marketer

Intas Pharmaceuticals Ltd

Salt Composition

Sitagliptin (50mg) + Metformin (500mg)

Overview Ignalis-M 50mg/500mg Tablet ER

Diabex Duo 50mg/500mg Extended-Release Tablets combine two medications to manage elevated blood glucose in individuals with type 2 diabetes. This dual action helps prevent serious diabetic complications like renal impairment and vision loss, potentially lowering the risk of cardiovascular events. Diabex Duo may be used independently or in conjunction with other antidiabetic therapies. Optimal results are achieved when combined with a balanced diet and regular physical activity. Dosage is personalized based on your health status, glucose levels, and current medications. Consuming it with food minimizes gastrointestinal discomfort. Consistent daily intake, at the same time each day, maximizes effectiveness; discontinuation should only occur under your physician's guidance. Adherence to your prescribed diet and exercise regimen is crucial. Lifestyle choices significantly influence diabetes control. Common side effects include diarrhea, nausea, vomiting, indigestion, headache, and pharyngitis. Hypoglycemia is a potential adverse effect, particularly when used with insulin or sulfonylureas; learn its recognition and management. This medication isn't appropriate for everyone. Inform your doctor of any history of kidney, liver, or heart disease, pancreatic issues, or significant alcohol consumption before starting treatment. Pregnant or lactating women should consult their physician prior to use. Drug interactions are possible; disclose all medications to ensure safety. Alcohol should be limited due to its hypoglycemic effects. Your doctor will monitor kidney function and blood sugar levels throughout your treatment.

Primary Ingredients of Ignalis-M 50mg/500mg Tablet ER

The provided text is "undefined," therefore no rephrasing is possible.

Uses of Ignalis-M 50mg/500mg Tablet ER

Managing type 2 diabetes

Major Benefits of Ignalis-M 50mg/500mg Tablet ER:

Follow your doctor's instructions precisely regarding dosage and treatment length for Ignalis-M 50mg/500mg Extended-Release tablets. Ingest the tablets whole; do not chew, crush, or divide them. Consume this medication with food.

Common Side effects of Ignalis-M 50mg/500mg Tablet ER:

  • Decreased appetite
  • Vomiting
  • Upper respiratory tract infection
  • Hypoglycemia (low blood glucose level)
  • Abdominal bloating
  • Nausea
  • Diarrhea

How to use Ignalis-M 50mg/500mg Tablet ER:

Follow your doctor's instructions precisely regarding the dosage and treatment length for this medication. The Ignalis-M 50mg/500mg Extended-Release tablet should be swallowed whole with a meal; do not break, crush, or chew it.

How Ignalis-M 50mg/500mg Tablet ER works:

Ignalis-M 50mg/500mg Extended-Release tablets combine sitagliptin and metformin to manage blood glucose. Sitagliptin enhances insulin production by the pancreas, improves insulin utilization, and decreases hepatic glucose output. Metformin, a biguanide, reduces liver glucose production, slows intestinal glucose absorption, and boosts insulin sensitivity. This dual action results in superior glycemic control.

SAFETY ADVICE

AlcoholAlcoholUNSAFE

Combining Ignalis-M 50mg/500mg Extended-Release tablets with alcohol is not recommended due to safety concerns.

PregnancyPregnancyCONSULT YOUR DOCTOR

Extended-release Ignalis-M 50mg/500mg tablets might pose risks during pregnancy. While human data is scarce, animal research indicates potential harm to a developing fetus. A physician will assess the advantages against possible dangers prior to prescribing. Seek medical advice.

Breast feedingBreast feedingCONSULT YOUR DOCTOR

Extended-release Ignalis-M 50mg/500mg tablets are likely not safe for breastfeeding mothers. Available human data indicate potential drug transfer to breast milk, posing a risk to the infant.

DrivingDrivingCAUTION

Driving ability can be impaired by both hypoglycemia and hyperglycemia. Refrain from driving if you experience these conditions.

KidneyKidneyCAUTION

Patients with impaired kidney function should use Ignalis-M 50mg/500mg Extended-Release tablets cautiously, potentially requiring dosage modification. Consult a physician for guidance. Ignalis-M 50mg/500mg Extended-Release tablets are contraindicated in patients with severe kidney disease. Regular monitoring of kidney function is recommended during treatment.

LiverLiverUNSAFE

Extended-release Ignalis-M 50mg/500mg tablets are likely contraindicated for individuals with hepatic impairment and should be omitted. Physician consultation is advised.

What if you forget to take Ignalis-M 50mg/500mg Tablet ER :

Should you forget to take your Ignalis-M 50mg/500mg Extended-Release tablet, administer it immediately upon remembering. However, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosing regimen. Never take more than the prescribed dose.

Facts to Know About Ignalis-M 50mg/500mg Tablet ER

LabelValue
Developing Habits No.
Type of Therapy Diabetes Management

FAQs on Ignalis-M 50mg/500mg Tablet ER

Ignalis-M 50mg/500mg Extended-Release tablets combine sitagliptin and metformin to manage type 2 diabetes in adults. This combination improves blood sugar control when used with diet and exercise. Metformin reduces liver glucose production and enhances insulin sensitivity, while sitagliptin increases insulin release by inhibiting DPP-4. This medication is not suitable for individuals under 18.
Prolonged use of Ignalis-M 50mg/500mg ER tablets can lead to vitamin B12 deficiency by hindering its absorption in the stomach. This deficiency may cause anemia, nerve damage (manifested as tingling, numbness in extremities, weakness, urinary issues, cognitive changes, and ataxia), if left unaddressed. To mitigate this risk, annual supplemental vitamin B12 is recommended by some researchers.
Ignalis-M 50mg/500mg ER tablets may cause common side effects such as hypoglycemia, altered taste, nausea, stomach pain, diarrhea, headache, and upper respiratory infections. Rare but serious side effects include lactic acidosis. Prolonged use may also result in vitamin B12 deficiency.
Patients with known allergies to Ignalis-M 50mg/500mg Tablet ER components or excipients, or those with severe kidney or liver impairment, congestive heart failure, lactic acidosis, or diabetic ketoacidosis, should not use this medication.
Combining Ignalis-M 50mg/500mg ER tablets with alcohol is unsafe and may raise your risk of lactic acidosis.
Store this medication in its original, tightly closed container, following the storage instructions on the packaging. Discard any unused medication and ensure it's kept out of reach of children, pets, and others.
Lactic acidosis, a serious medical emergency (also known as MALA, or Metformin-associated lactic acidosis), is a potential side effect of Ignalis-M 50mg/500mg Tablet ER. This occurs due to excessive lactic acid buildup in the blood. Because it's rare, metformin use is avoided in patients with kidney disease, the elderly, and heavy alcohol consumers. Symptoms include muscle pain/weakness, dizziness, fatigue, cold extremities, shortness of breath, nausea/vomiting, abdominal pain, and bradycardia. If these occur, discontinue Sitagliptin + Metformin and seek immediate medical attention.
Ignalis-M 50mg/500mg Extended-Release tablets combine sitagliptin and metformin to manage type 2 diabetes in adults. This combination improves blood sugar control when used with diet and exercise. Metformin reduces liver glucose production and enhances insulin sensitivity, while sitagliptin increases insulin release by inhibiting DPP-4. This medication is not suitable for individuals under 18 years old.
Ignalis-M 50mg/500mg ER tablets may cause common side effects such as hypoglycemia, altered taste, nausea, stomach pain, diarrhea, headache, and upper respiratory infections. Rare but serious side effects include lactic acidosis. Prolonged use can also result in vitamin B12 deficiency.
Patients with known allergies to Ignalis-M 50mg/500mg Tablet ER components or excipients, or those with severe kidney or liver impairment, congestive heart failure, lactic acidosis, or diabetic ketoacidosis should not use this medication.
Combining Ignalis-M 50mg/500mg Tablet ER with alcohol is unsafe and may raise your risk of lactic acidosis.
Yes, Ignalis-M 50mg/500mg ER tablets can cause lactic acidosis, a serious medical emergency resulting from excessive blood lactic acid. Also known as metformin-associated lactic acidosis (MALA), this rare side effect necessitates caution in patients with kidney disease, the elderly, or those who consume significant alcohol. Symptoms include muscle pain/weakness, dizziness, fatigue, cold extremities, shortness of breath, nausea, vomiting, abdominal pain, and bradycardia. If you experience these, discontinue Sitagliptin + Metformin and seek immediate medical attention.
Prolonged use of Ignalis-M 50mg/500mg ER tablets can lead to vitamin B12 deficiency by hindering its absorption in the stomach. This deficiency can cause anemia and neurological issues, manifesting as numbness and tingling in the extremities, weakness, urinary difficulties, cognitive changes, and balance problems (ataxia). To mitigate these risks, annual supplemental vitamin B12 intake is recommended by some researchers.
Store this medication in its original, tightly closed container, following the storage instructions on the label or packaging. Dispose of any unused medication properly and ensure it's inaccessible to children, pets, and others.
Ignalis-M 50mg/500mg Extended-Release tablets combine sitagliptin and metformin to manage type 2 diabetes in adults. This combination improves blood sugar control when used with diet and exercise. Metformin reduces liver glucose production and enhances insulin sensitivity, while sitagliptin boosts insulin release by inhibiting DPP-4. This medication is not suitable for individuals under 18.
Ignalis-M 50mg/500mg ER tablets may cause common side effects such as hypoglycemia, altered taste, nausea, stomach pain, diarrhea, headache, and upper respiratory infections. Rare but serious side effects include lactic acidosis. Prolonged use can also result in vitamin B12 deficiency.
Patients with known allergies to Ignalis-M 50mg/500mg Tablet ER components or excipients, or those with severe kidney or liver impairment, congestive heart failure, lactic acidosis, or diabetic ketoacidosis should not use this medication.
Combining Ignalis-M 50mg/500mg Tablet ER with alcohol is unsafe and may heighten the risk of lactic acidosis.
Lactic acidosis, a serious medical emergency characterized by excess blood lactic acid (also known as MALA when linked to metformin), is a potential side effect of Ignalis-M 50mg/500mg Tablet ER. This rare complication is more likely in patients with kidney disease, the elderly, or those who consume excessive alcohol, hence its avoidance in these groups. Symptoms include muscle pain/weakness, dizziness, fatigue, cold extremities, shortness of breath, nausea, vomiting, abdominal pain, and bradycardia. Should these symptoms arise, discontinue Sitagliptin + Metformin and seek immediate medical attention.
Prolonged use of Ignalis-M 50mg/500mg Extended-Release tablets can lead to vitamin B12 deficiency by hindering its absorption. This deficiency may cause anemia, nerve damage (manifesting as tingling, numbness in extremities, weakness, and urinary issues), and cognitive changes including balance problems (ataxia). To mitigate these risks, supplemental vitamin B12 is recommended annually by some researchers.
Store this medication in its original, tightly closed container, following the storage instructions on the label. Discard any unused medication and keep it out of reach of children, pets, and others.
Ignalis-M 50mg/500mg Tabl...
142
MRP 165
13% off